HELP — Cybin Inc. Common Stock

Summary of Cybin's Q2 2026 Earnings Call

1. Key Financial Results and Metrics:

• Cash-Based Operating Expenses: $28.5 million for Q2 2026, up from $18.2 million in Q2 2025.
• Net Loss: $33.7 million for the quarter, compared to a net loss of $41.9 million in the prior year.
• Cash Flows Used in Operating Activities: $34.5 million, increased from $19.1 million year-over-year.
• Operating Loss: $28.9 million.
• Cash Position: Ended the quarter with $83.8 million. Following a $175 million financing, the company has sufficient resources to fund operations into 2027.

2. Strategic Updates and Business Highlights:

• Leadership Transition: Eric So is serving as Interim CEO following Doug Drysdale's departure. A search for a permanent CEO is ongoing.
• Pipeline Progress:
  • CYB003: In Phase III for major depressive disorder (MDD) with additional clearances for the EMBRACE study in new geographies.
  • CYB004: Phase II study for generalized anxiety disorder (GAD) completed enrollment and is on track for top-line data in Q1 2026.
• Operational Focus: Emphasis on creating practical therapy days in clinics, reducing patient visit burdens, and ensuring a predictable workflow without the need for new infrastructure.
• Manufacturing and Commercial Readiness: Partnerships with Thermo Fisher and Osmind to ensure reliable supply and integration into existing clinic operations.

3. Forward Guidance and Outlook:

• CYB003: Dosing continues with a goal of completing enrollment in the APPROACH trial by mid-2026 and delivering top-line data by the end of 2026.
• CYB004: Anticipates sharing data on the primary endpoint (HAM-A) in Q1 2026, with a focus on demonstrating meaningful clinical improvements.
• Capital Deployment: Resources are being allocated toward measurable milestones, with a disciplined approach to spending.

4. Bad News, Challenges, or Points of Concern:

• Increased Operating Expenses: Year-over-year rise in cash-based operating expenses raises concerns about cost management.
• Leadership Transition Risks: The ongoing CEO search may create uncertainty in strategic direction and execution.
• Market Competition: The company faces competition from established treatments like SPRAVATO, necessitating clear differentiation in product profiles and efficacy.
• Regulatory Engagement: Maintaining a conservative regulatory posture may slow progress in some areas, particularly in demonstrating long-term efficacy and safety.

5. Notable Q&A Insights:

• CYB004 Study Expectations: The focus is on achieving directional data and potential statistical significance in the upcoming readout, with a minimum clinically meaningful improvement of 4-5 points on the HAM-A scale.
• CYB003 Compliance: Patients are required to remain on background antidepressant medications during the trial, which is crucial for the study's integrity.
• Payer Engagement: Early discussions with payers are ongoing, but it is still premature to draw conclusions about market positioning against existing treatments.
• CEO Qualities: The ideal candidate should have a proven track record in drug commercialization, capital stewardship, and experience with big pharma.

Overall, Cybin is navigating a pivotal period with significant clinical milestones ahead while managing operational costs and leadership transitions. The focus remains on executing its strategic plan and preparing for upcoming data readouts.